[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE357237T1 - Formulierungen enthaltend cefuroxim-axetil - Google Patents

Formulierungen enthaltend cefuroxim-axetil

Info

Publication number
ATE357237T1
ATE357237T1 AT99959327T AT99959327T ATE357237T1 AT E357237 T1 ATE357237 T1 AT E357237T1 AT 99959327 T AT99959327 T AT 99959327T AT 99959327 T AT99959327 T AT 99959327T AT E357237 T1 ATE357237 T1 AT E357237T1
Authority
AT
Austria
Prior art keywords
cefuroxim
axetil
formulations containing
formulations
containing cefuroxim
Prior art date
Application number
AT99959327T
Other languages
English (en)
Inventor
Herwig Jennewein
Johannes Raneburger
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Application granted granted Critical
Publication of ATE357237T1 publication Critical patent/ATE357237T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
AT99959327T 1998-11-26 1999-11-24 Formulierungen enthaltend cefuroxim-axetil ATE357237T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0198998A AT413647B (de) 1998-11-26 1998-11-26 Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten
PCT/EP1999/009096 WO2000030647A1 (en) 1998-11-26 1999-11-24 Compositions comprising cefuroxime axetil

Publications (1)

Publication Number Publication Date
ATE357237T1 true ATE357237T1 (de) 2007-04-15

Family

ID=3525440

Family Applications (3)

Application Number Title Priority Date Filing Date
AT0198998A AT413647B (de) 1998-11-26 1998-11-26 Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten
AT99959327T ATE357237T1 (de) 1998-11-26 1999-11-24 Formulierungen enthaltend cefuroxim-axetil
AT0028104A AT500135A1 (de) 1998-11-26 2004-02-23 Organische verbindungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT0198998A AT413647B (de) 1998-11-26 1998-11-26 Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT0028104A AT500135A1 (de) 1998-11-26 2004-02-23 Organische verbindungen

Country Status (30)

Country Link
US (1) US6727243B1 (de)
EP (1) EP1133298B1 (de)
JP (1) JP2002530338A (de)
KR (1) KR20010080566A (de)
CN (1) CN1330546A (de)
AR (1) AR021405A1 (de)
AT (3) AT413647B (de)
AU (1) AU759517B2 (de)
BR (1) BR9915694A (de)
CA (1) CA2348876A1 (de)
CO (1) CO5190668A1 (de)
CZ (1) CZ20011845A3 (de)
DE (1) DE69935609T2 (de)
ES (1) ES2285866T3 (de)
HU (1) HUP0104412A3 (de)
ID (1) ID28615A (de)
IL (1) IL142762A0 (de)
MY (1) MY129564A (de)
NO (1) NO20012526D0 (de)
NZ (1) NZ511588A (de)
PE (1) PE20001326A1 (de)
PL (1) PL348744A1 (de)
RU (1) RU2248794C2 (de)
SI (1) SI1133298T1 (de)
SK (1) SK7162001A3 (de)
TR (1) TR200101417T2 (de)
TW (1) TWI229603B (de)
WO (1) WO2000030647A1 (de)
YU (1) YU34601A (de)
ZA (1) ZA200103927B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100342943B1 (ko) * 1999-08-04 2002-07-02 민경윤 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물
US7527807B2 (en) * 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
AU2001230490A1 (en) * 2000-12-01 2002-06-11 Arun Shriniwas Gosavi Pharmaceutical formulation
EP1911462A3 (de) * 2001-01-26 2011-11-30 Schering Corporation Zusammensetzungen enthaltend einen Sterolabsorptionshemmer
US6524617B1 (en) * 2001-07-25 2003-02-25 Isp Investments Inc. Synergistic filler composition
MY148466A (en) 2001-10-26 2013-04-30 Merck Frosst Canada Ltd Granule formulation
ES2201932B2 (es) * 2001-11-23 2005-03-16 Glaxo Group Limited Composicion farmaceutica.
JP4526247B2 (ja) * 2002-07-08 2010-08-18 第一三共株式会社 経口用セファロスポリン製剤
TW200404550A (en) * 2002-07-08 2004-04-01 Sankyo Co Cepharospolin formulation for oral use
AU2003260803A1 (en) * 2002-08-30 2004-03-19 Orchid Chemicals And Pharmaceuticals Ltd. Sustained release pharmaceutical composition
WO2005002540A2 (en) * 2003-07-01 2005-01-13 Ranbaxy Laboratories Limited Dry powder pharmaceutical suspension compositions of cefuroxime axetil
KR100552567B1 (ko) * 2003-08-23 2006-02-15 한국유나이티드제약 주식회사 수분 흡수에 안정하고 빠르게 붕해되는 세푸록심 악세틸을포함하는 정제의 조성물 및 제조 방법
CA2606386C (en) * 2005-04-29 2014-06-10 Cubist Pharmaceuticals, Inc. Therapeutic compositions
CN100402035C (zh) * 2005-07-07 2008-07-16 石药集团中奇制药技术（石家庄）有限公司 一种微囊化头孢呋辛酯的药物组合物
CA2800442C (en) 2010-06-14 2018-05-22 Ratiopharm Gmbh Ivabradine-containing pharmaceutical composition with modified release
WO2014023710A1 (en) * 2012-08-07 2014-02-13 Sandoz Ag UNCOATED TABLET COMPRISING GRANULES INCLUDING A β-LACTAM ANTIBIOTIC AND HIGHLY DISPERSED SILICONE DIOXIDE
WO2014174846A1 (ja) 2013-04-25 2014-10-30 杏林製薬株式会社 固形医薬組成物
JP5700740B1 (ja) 2013-04-25 2015-04-15 杏林製薬株式会社 固形医薬組成物
JP6018334B2 (ja) 2014-10-23 2016-11-02 杏林製薬株式会社 固形医薬組成物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1571683A (en) * 1976-02-16 1980-07-16 Glaxo Operations Ltd Ester derivatives of cefuroxime
GB1572993A (en) * 1976-02-16 1980-08-13 Glaxo Operations Ltd Ester derivatives of cefuroxime
YU44680B (en) 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
IL85538A (en) * 1987-02-27 1991-09-16 Lilly Co Eli Sustained release matrix tablet formulations containing hydrophilic and enteric polymers
NL193682C (nl) 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
DE3810343A1 (de) * 1988-03-26 1989-10-05 Basf Ag Verfahren zur herstellung von festen pharmazeutischen retardformen
DE4139963A1 (de) * 1991-12-04 1993-06-09 Basf Ag, 6700 Ludwigshafen, De Redispergierbares dispersionspulver aus n-vinylpyrrolidon-vinylacetat-copolymerisat, dessen herstellung und verwendung
DE19602757A1 (de) * 1996-01-26 1997-07-31 Boehringer Mannheim Gmbh Feste Instant-Release-Darreichungsformen und Verfahren zu ihrer Herstellung
US5663258A (en) * 1996-02-20 1997-09-02 Isp Investments Inc. Strongly swellable, moderately crosslinked copolymers of vinylpyrrolidone and vinyl acetate
DE19631085A1 (de) * 1996-08-01 1998-02-05 Basf Ag Verwendung von (Meth)acrylsäure-Maleinsäure-Copolymeren zur Verbesserung der Permeabilität der Schleimhaut
AU744156B2 (en) * 1996-10-28 2002-02-14 General Mills Inc. Embedding and encapsulation of controlled release particles
IL119627A (en) * 1996-11-17 2002-03-10 Yissum Res Dev Co PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED-RELEASE OF AN ACTIVE AGENT COMPRISING AT LEAST ONE β-LACTAM ANTIBIOTIC AGENT
CA2209868C (en) 1997-08-15 2001-08-14 Bernard Charles Sherman Pharmaceutical compositions comprising cefuroxime axetil
AU3277899A (en) * 1998-03-03 1999-09-20 Dae Woong Chemical Co., Ltd. Pharmaceutical composition containing cefuroxime axetil stable for moisture absorption
CA2239331C (en) 1998-05-29 1999-11-30 Bernard Charles Sherman Pharmaceutical tablets comprising cefuroxime axetil
DE19835823A1 (de) 1998-08-10 1999-10-07 Lindopharm Gmbh Pharmazeutische Zusammensetzung, Verfahren zu ihrer Herstellung und ihre Verwendung sowie aus ihr hergestellte wässerige Suspension
KR100342943B1 (ko) 1999-08-04 2002-07-02 민경윤 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물

Also Published As

Publication number Publication date
IL142762A0 (en) 2002-03-10
EP1133298A1 (de) 2001-09-19
HUP0104412A3 (en) 2002-08-28
CO5190668A1 (es) 2002-08-29
DE69935609T2 (de) 2007-12-06
PE20001326A1 (es) 2000-12-12
YU34601A (sh) 2004-09-03
NZ511588A (en) 2003-08-29
RU2248794C2 (ru) 2005-03-27
AU1654400A (en) 2000-06-13
AR021405A1 (es) 2002-07-17
TR200101417T2 (tr) 2001-11-21
MY129564A (en) 2007-04-30
US6727243B1 (en) 2004-04-27
CZ20011845A3 (cs) 2001-08-15
ZA200103927B (en) 2002-05-15
ID28615A (id) 2001-06-21
PL348744A1 (en) 2002-06-03
SK7162001A3 (en) 2001-10-08
EP1133298B1 (de) 2007-03-21
CN1330546A (zh) 2002-01-09
DE69935609D1 (de) 2007-05-03
ATA198998A (de) 2005-09-15
AT413647B (de) 2006-04-15
TWI229603B (en) 2005-03-21
HUP0104412A2 (hu) 2002-04-29
AU759517B2 (en) 2003-04-17
JP2002530338A (ja) 2002-09-17
WO2000030647A1 (en) 2000-06-02
NO20012526L (no) 2001-05-23
KR20010080566A (ko) 2001-08-22
ES2285866T3 (es) 2007-11-16
CA2348876A1 (en) 2000-06-02
AT500135A1 (de) 2005-11-15
BR9915694A (pt) 2001-08-14
SI1133298T1 (sl) 2007-10-31
NO20012526D0 (no) 2001-05-23

Similar Documents

Publication Publication Date Title
IS5555A (is) Selekoxib lyfjablöndur
ID30031A (id) Formulasi-formulasi agrokimia
ID23546A (id) Formulasi-formulasi ziprasidon
NO20004240L (no) Formuleringer
ATE224703T1 (de) Brauseformulierungen
PT1130966E (pt) Formulacoes antiparasitarias
NL300371I1 (nl) Ranolazine bevattende formuleringen met langdurigeafgifte
IS2325B (is) Örgerðar samsetningar epleróns
MA24473A1 (fr) Formulations
DE69805443D1 (de) Sachet-formulierungen
DE69832516D1 (de) Isoflavon-enthaltende zusammensetzungen
ID23299A (id) Formulasi-formulasi farmasi
DE69836106D1 (de) Stanolester enthaltende Zusammensetzungen
ID26186A (id) Komposisi sampo
ID28694A (id) Komposisi sampo
ID29635A (id) Formulasi mikrokapsul
CY2006006I1 (el) Πρωτεϊνικα σκευασματα
ID23458A (id) Bentuk sediaan nefazodon
DE69942892D1 (de) Gaserzeugende zusammensetzung
DE69928862D1 (de) Zusammensetzung
DE69935609D1 (de) Formulierungen enthaltend cefuroxim-axetil
ID27655A (id) Formulasi mikrokapsul
NO20005722D0 (no) Brusetilberedninger
ID26295A (id) Komposisi keras-ultraviolet
ID26485A (id) Komposisi paroksetina

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1133298

Country of ref document: EP